Gonazlez Vicent et al (2018) report on a study in ruxolitinib in SR acute GvHD in children:
"We employed a lower dose of ruxolitinib of 2.5mg once daily in two infants with acute GvHD"
Khandelwal et al (2017) report on a study in ruxolitinib in SR acute GvHD in children with a mean age of 8.5 years.
Rux is being given to young children even though the dose hasn't been established.
I don't understand your point about throwing shade to feed the shorters. I used this very fact, that rux was being given to very young children on compassionate grounds when it hadn't been approved and the dose hadn't even been established for children, as a stick to beat the FDA with in my letter (essay) to them, a sign of a desperate situation that they can't allow to go on.
No, rux isn't saving any lives. There's compelling evidence it's causing more deaths than if it had never been approved. Reach2 showed no mortality benefit despite being trialled against highly questionable choice of BAT in almost 50% of cohort. I went through these therapies in detail. Look up Reach1 and see how many patients died by day 28.
Rux has benefit in mild/moderate skin GvHD but even then it hasn't negated the need for expensive in-hospital therapy. ECP is still widely used and rux is often added to kick things on. Patients have to attend hospital for most of the day for ECP, several times a week, for months or even years. There is also nothing for lung GvHD, which is a major cause of morbidity and mortality.
MSB Price at posting:
$1.77 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)